Trial Group - Gastrointestinal

Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction).

This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy.

Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy.

Cancer of the oesophagus or gastro-oesophageal junction which has spread (metastasised).

To compare survival between the two groups – those treated with Trastuzumab, chemotherapy and Pembrolizumab and those treated with Trastuzumab, chemotherapy and placebo.

Patients with cancer of the colon or rectum which has spread (metastasised).

To find and test new stratification tools (ways of dividing patients into different groups) in patients who have microsatellite stable RAS mutant metastatic colorectal cancer.

Cancer of the oesophagus, or the junction between the oesophagus and the stomach.

The purpose of this trials is to determine the effectiveness of the drug nivolumab in patients with residual disease after CRT and surgery.

Cancer of the colon or rectum.

The purpose of this trial is to compare two standard chemotherapy treatment strategies.

Cancer of the colon.

The purpose of this trial is to examine the effectiveness of the drug Nivolumab in combination with other drugs.

Cancer of the rectum.

The purpose of this trial is to compare two radiotherapy techniques for treating locally advanced rectal cancer.

Pancreatic cancer

The purpose of this trial is to investigate how proteins and genes respond to pancreatic cancer treatment.

Colorectal cancer (colon or rectal)

The purpose of this trial is to investigate what proteins and genes are related to the recurrence of colorectal cancer.

Cancer of the oesophagus or the junction between the oesophagus and the stomach.

The aim of this trial is to compare and evaluate two well-established standard of care treatments for cancer of the oesophagus in order to establish if one treatment is better than the other.